
About GT Biopharma
GT Biopharma is a publicly listed company based in Washington (United States) founded in 1965 by Anthony Cataldo. Immunotherapies for cancer treatment are developed using proprietary platforms. The company has 1 employees. GT Biopharma offers products and services including TriKE Therapies. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory. Its legal entity in India is G T Biopharma Private Limited (U24234DL2007PTC165068). Similar companies include Moderna, Roivant Sciences and BeiGene; 3 of its 3 listed similar companies have raised funding.
Company details
GT Biopharma was founded in 1965 and operates in the biotechnology sector, where immunotherapies are developed for cancer treatment. Proprietary platform technology is utilized to create biopharmaceutical drugs targeting conditions such as acute lymphocytic leukemia, non-Hodgkins lymphoma, acute myeloid leukemia, and various solid tumors. Operations focus on immuno-oncology advancements without specified geographic limitations.
- Headquarters Washington, United States
- Employees 1
- Founders Anthony Cataldo
- Stage Public
- SectorsHealthcare
- Website gtbiopharma.com
- Social LinkedIn X
- Legal Name Gt Biopharma, Inc.
- Net Profit-$28.35 M (USD)-115.42as on Dec 31, 2025
- EBITDA-$12.42 M (USD)13.52as on Dec 31, 2025
- Latest Funding Round$5.95M (USD), Post-IPO
May 2025
- Employee Count1
Associated legal entities of GT Biopharma
GT Biopharma operates through G T Biopharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| G T Biopharma Private Limited CIN U24234DL2007PTC165068 | Active | 21 Jun 2007 | New Delhi, Delhi | 2 | View details |
Products & Services of GT Biopharma
GT Biopharma offers a comprehensive portfolio of products and services, including TriKE Therapies.
Biopharmaceutical agents that engage NK cells to target and kill cancer cells.
Funding Insights of GT Biopharma
- Total Rounds 9
- Last Round Post-IPO โ $5.95M
- First Round $1.43M
(Jul 2014)
All 9 funding rounds of GT Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2025 | $5.95M | Post-IPO | โ | โ | โ |
| Feb 2025 | $1.28M | Post-IPO | โ | โ | โ |
| Jul 2020 | $2.42M | Post-IPO | โ | โ | โ |
| Feb 2019 | $1.05M | Post-IPO | โ | โ | โ |
| Aug 2018 | $5.14M | Post-IPO | โ | โ | โ |
| Feb 2018 | $7.06M | Post-IPO | โ | โ | โ |
| Sep 2017 | $4.54M | Post-IPO | โ | โ | โ |
| Mar 2015 | $2.05M | Post-IPO | โ | โ | โ |
| Jul 2014 | $1.43M | Post-IPO | โ | โ | โ |
Board of directors of G T Biopharma Private Limited (GT Biopharma)
G T Biopharma Private Limited is the primary company behind GT Biopharma. The board of G T Biopharma Private Limited currently have 2 directors; the longest-serving is Mukesh Bhasin, appointed in 2007. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mukesh Bhasin DIN 01061327 | Director | 21 Jun 2007 | 19 yrs 4 mo | G T Biopharma Private Limited |
| Sanjay Kumar Bhartia DIN 00275439 | Director | 21 Jun 2007 | 19 yrs 4 mo | G T Biopharma Private Limited |
People of GT Biopharma
12 people are tracked at GT Biopharma (5 in leadership, 4 in board & advisors, 3 in team); the tracked headcount is 1.
| Name | Role | Group |
|---|---|---|
Anthony Cataldo | Founder | Leadership |
Manu Ohri | CFO | Leadership |
Michael Breen | Executive Chairman & Interim CEO | Leadership |
Gavin Choy | Chief Clinical Development Officer | Leadership |
Alan L. Urban | Chief Financial Officer | Leadership |
Lisa A. Haile | Scientific Advisor | Board & advisors |
Arjun V Balar | Scientific Advisor | Board & advisors |
Philip Werthman | Scientific Advisor | Board & advisors |
Samir Taneja | Scientific Advisor | Board & advisors |
Jeffrey S. Miller | Consulting CSO | Team |
Stacy Herb | SVP, Portfolio Management | Team |
Julianne Feola | Clinical Operations Consultant | Team |
Complete people profiles for GT Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of GT Biopharma
GT Biopharma is a publicly listed company on the NASDAQ with ticker symbol GTBP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Oct 2013
- Listed onNASDAQ: GTBP
- Listed entityGT Biopharma, Inc.
- Exchange sectorHealth technology
- ISINUS36254L4077
- Share price$6.50 (-4.41% on the day) · 2026-10-13
- Market capitalisation$13.4M
- EPS (diluted, trailing year)$-90.07
- Volume (last session)29,555
Financials of GT Biopharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$28.4M | -$12.4M | |
| 2024 | -$13.2M | -$14.4M | |
| 2023 | -$7.6M | -$13.6M | |
| 2022 | -$20.9M | -$21.3M | |
| 2021 | -$58.0M | -$57.8M |
Balance sheet, profit and loss, cash flow and ratios of G T Biopharma Private Limited are on its company page.
Detailed financial statements for GT Biopharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of GT Biopharma
4 dated milestones of GT Biopharma across 60 years, from founding to its latest funding, stage changes and deals.
- Founded GT Biopharma is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.4M.
- Funding Latest funding round, Post-IPO, of $6.0M.
Similar companies to GT Biopharma
GT Biopharma has 3 listed similar companies in our database, 3 of them funded. They include Moderna, Roivant Sciences and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed similar companies of GT Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GT Biopharma
The website of GT Biopharma (gtbiopharma.com) receives about 3.7K visits a month.
- Monthly visits3.7K
▼ 26.7% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as GT Biopharma (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track โ from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Gt Biopharma
Complete news archive for GT Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GT Biopharma
GT Biopharma was founded in 1965 and raised its 1st funding round 49 years after it was founded.
GT Biopharma is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.
GT Biopharma has 1 employees.
GT Biopharma was founded in 1965 and operates in the biotechnology sector, where immunotherapies are developed for cancer treatment. Proprietary platform technology is utilized to create biopharmaceutical drugs targeting conditions such as acute lymphocytic leukemia, non-Hodgkins lymphoma, acute myeloid leukemia, and various solid tumors. Operations focus on immuno-oncology advancements without specified geographic limitations.
GT Biopharma's top competitors include Moderna, Roivant Sciences and BeiGene.
GT Biopharma offers TriKE Therapies.
Yes, GT Biopharma is publicly traded on NASDAQ under the ticker symbol GTBP.
GT Biopharma operates through G T Biopharma Private Limited.
The legal entities of GT Biopharma currently have 2 directors, including Mukesh Bhasin, Sanjay Kumar Bhartia.
